Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT00475670
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT00475423
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT00475072
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT00474955
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00472420
- Locations
- ππΊ
University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology, Debrecen, Hungary
ππΊKaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology, Kaposvar, Hungary
ππΊZala Megyei Korhaz; Ii. Belgyogyaszat, Zalaegerszeg, Hungary
Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial
Not Applicable
Withdrawn
- Conditions
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00468702
A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT00468754
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 520
- Registration Number
- NCT00468546
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT00462384
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT00462345
Β© Copyright 2024. All Rights Reserved by MedPath